2905 Amprenavir Amprenavir is an exogenous antiviral drug and HIV protease inhibitor with the chemical formula C25H35N3O6S. At room temperature, this compound exists as a solid. Amprenavir belongs to the benzenesulfonamides, a subclass of benzene and substituted derivatives within the organic compounds. With an average molecular weight of 505.63 g/mol, Amprenavir is a heavy molecule. The compound is utilized as a biological and chemical HIV protease inhibitor. It has been recorded in seven sources, including healthcare, pharmaceuticals and veterinary products such as antivirals; household cleaning and consumer products, specifically non electric simulated smoking devices; and electrical and electronic equipment, including antennas, magnets, relays, television systems, and video games. The recorded route of exposure for this substance is oral. In terms of protein targets, Amprenavir is an inhibitor of seven recorded proteins. These include the ATP-dependent translocase ABCB1, Cathepsin D (CTSD), Cytochrome P450 3A4 (CYP3A4), and Cytosolic 10-formyltetrahydrofolate dehydrogenase (ALDH1L1), along with three other proteins. 161814-49-9 65016 C25H35N3O6S 505.224660 White powder. 4.91e-02 g/L Rapidly absorbed after oral administration in HIV-1-infected patients with a time to peak concentration (T_max) typically between 1 and 2 hours after a single oral dose. The absolute oral bioavailability of amprenavir in humans has not been established. Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Hepatic. Amprenavir is metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system. The 2 major metabolites result from oxidation of the tetrahydrofuran and aniline moieties. Glucuronide conjugates of oxidized metabolites have been identified as minor metabolites in urine and feces. Half Life: 7.1-10.6 hours No indication of carcinogenicity to humans (not listed by IARC). For the treatment of HIV-1 infection in combination with other antiretroviral agents. If overdosage occurs, the patient should be monitored for evidence of toxicity and standard supportive treatment applied as necessary. (L1712) 2009-07-21T20:27:27Z 2026-05-14T16:46:28Z Amprenavir C08086 2684 Amprenavir DB00701 478 true CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 C25H35N3O6S InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1 YMARZQAQMVYCKC-OEMFJLHTSA-N 505.627 505.224656557 Exogenous Solid 2.43 HMDB14839 CHEMBL116 58532 <p><a href="http://www.drugsyn.org/Amprenavir.htm">DrugSyn.org</a></p> CHEM002251 DTXSID5046061 NS00004082 (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)4-aminobenzenesulfonamido]-1-phenylbutan-2-yl]carbamate 131.19 134.0815 53.60424163797374 11 6 3 13.614255356778301 2.3863099248148067 0 3 1.85 -4.01 4.91e-02 g/l Organic compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides 902 CED0005536 YMARZQAQMVYCKC-OEMFJLHTSA-N 40000000800000000001800000000500000000008000000000008000100000000000003000000001000000020000000004000000120000000000000000000000001000000000000000000000010000000020800000000100001800000000000000000000010100000400004000044080000000020020020000000000000000100000000040200000800000000200004080009000020100000000000000000000000000000004a00000000000080001000000000000004000080000000000000000000000000000000000000000000000000000000000000000000222001000000008000000000100080040000000000410000020000000000000000000020000 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 776t3gAAAAAQAAAAAwAAAAAAAAAjAAAAJQAAAIABBgBgAAAAAQMGAGAAAAAD AQYAYAAAAAEDBgBgAAAAAgIHACAAAAADBgBgAAAAAgIGIDQAAAABAQQIAGAA AAABAQYgNAAAAAIBBAYAYAAAAAICBkAoAAAAAwQGQGgAAAADAwEGQGgAAAAD AwEGQGgAAAADAwEGQGgAAAADAwEGQGgAAAADAwEHAGgAAAADAgEGACgAAAAD BAgAKAAAAAMCCAAoAAAAAwIGIDQAAAABAQQGAGAAAAACAgYAYAAAAAICCAAg AAAAAgYAYAAAAAICEAAgAAAABggAKAAAAAMCCAAoAAAAAwIGQCgAAAADBAZA aAAAAAMDAQZAaAAAAAMDAQZAKAAAAAMEBwBoAAAAAwECBkBoAAAAAwMBBkBo AAAAAwMBCwABAAECAAEDAAMEAAQFAAUGAAYHAAYIAAgJAAkKAAoLaAwLDGgM DA1oDA0OaAwOD2gMCBAAEBEgERIoAhETIBMUABQVABUWABYXABcYAAQZABka CAIZGwgCGRwAHB1oDB0eaAweH2gMHyAgHyFoDCEiaAwPCmgMGBQAIhxoDEID AAAABgsMDQ4PCgUVFBgXFgYdHh8hIhwXBAAAAAAAAAAW 2026-09-19T04:00:37Z